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Abstract
Background: The objective of this study was to determine whether: (a) markers of acute inflammation (white cell count,
glucose, interleukin-6, C-reactive protein, and fibrinogen) are associated with poor outcome after stroke and (b) the addition
of markers to previously validated prognostic models improves prediction of poor outcome.
Methods and Findings: We prospectively recruited patients between 2002 and 2005. Clinicians assessed patients and drew
blood for inflammatory markers. Patients were followed up by postal questionnaire for poor outcome (a score of.2 on the
modified Rankin Scale) and death through the General Register Office (Scotland) at 6 mo. We performed a systematic review
of the literature and meta-analysis of the association between interleukin-6 and poor outcome after stroke to place our
study in the context of previous research. We recruited 844 patients; mortality data were available in 844 (100%) and
functional outcome in 750 (89%). After appropriate adjustment, the odds ratios for the association of markers and poor
outcome (comparing the upper and the lower third) were interleukin-6, 3.1 (95% CI: 1.9–5.0); C-reactive protein, 1.9 (95% CI:
1.2–3.1); fibrinogen, 1.5 (95% CI: 1.0–2.36); white cell count, 2.1 (95% CI: 1.3–3.4); and glucose 1.3 (95% CI: 0.8–2.1). The
results for interleukin-6 were similar to other studies. However, the addition of inflammatory marker levels to validated
prognostic models did not materially improve model discrimination, calibration, or reclassification for prediction of poor
outcome after stroke.
Conclusions: Raised levels of markers of the acute inflammatory response after stroke are associated with poor outcomes.
However, the addition of these markers to a previously validated stroke prognostic model did not improve the prediction of
poor outcome. Whether inflammatory markers are useful in prediction of recurrent stroke or other vascular events is a
separate question, which requires further study.
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Introduction
A nonspecific systemic inflammatory response occurs after both
ischemic and hemorrhagic stroke, either as part of the process of
brain damage or in response to complications such as deep venous
thrombosis. Several studies have reported that higher levels of
inflammatory markers such as C-reactive protein (CRP) and
interleukin-6 (IL-6) are associated with worse outcome after both
ischemic [1] and hemorrhagic [2,3] strokes. However, these
studies often had methodological weaknesses, chiefly that they
were too small, did not adequately adjust for confounders or assess
the clinical utility of the measurements.
The addition of markers of inflammation to validated clinical
prognostic models might improve the prediction of poor outcome
after stroke. There are at least two validated models for predicting
clinical outcome after stroke; one is based on six simple clinical
variables [4] that can be applied without specific training, and the
other includes the more complex National Institutes of Health
Stroke Scale (NIHSS) (it measures 15 items and requires training)
and age [5].
We therefore aimed to validate the suggestion that several
markers of the acute phase response—CRP, IL-6, white cell count,
fibrinogen, or glucose—are reliably associated with poor outcome
after ischemic and hemorrhagic stroke in a large prospective
cohort of stroke patients. We then wished to assess whether they
improved prognostic models in the same cohort.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Lothian Research Ethics Committee. All patients or their relatives
provided written informed consent for the collection of samples
and subsequent analysis.
Patients
We prospectively recruited all consenting patients with recent
stroke from the emergency department; medical, neurology, and
occasionally other (e.g., surgical) wards; stroke unit; and
neurovascular clinics of the Western General Hospital, Edinburgh,
United Kingdom, between April 2002 and May 2005 into the
Edinburgh Stroke Study [6]. Clinicians recorded data at the time
of assessment using a standardised structured pro forma and, in
patients who consented, drew blood for measurement of
inflammatory markers.
We defined a clinically definite stroke as new clinical symptoms
or signs of a focal disturbance of cerebral function lasting more
than 24 h of a vascular origin. We excluded patients with
subarachnoid hemorrhage. At a weekly meeting, stroke physicians,
neurologists, and neuroradiologists reviewed the clinical features of
each patient, all brain images, and clinical progress. We defined an
ischemic stroke as a clinically definite stroke in a patient whose
brain imaging showed either positive evidence of a relevant
ischemic lesion or was normal and excluded intracranial
haemorrhage and stroke mimics. We diagnosed a stroke as an
intracerebral hemorrhage if the patient’s clinical features and
brain imaging were consistent with acute hemorrhage. We defined
pathological subtype of stroke as probably ischemic in patients
with a clinically definite stroke in whom the radiological results
were equivocal or unavailable and analysed them together with
definite ischemic strokes. We assigned a final ischemic stroke
syndrome according to the Oxford Community Stroke Project
(OCSP) classification [7] based on the clinical syndrome at the
time of maximum deficit modified, where appropriate, by the site
and size of relevant infarcts on brain imaging. The diagnosis of
stroke was made blinded to the measurement of CRP, IL-6, and
fibrinogen.
Measurement of Clinical Variables
A physician with experience in stroke medicine assessed each
patient as soon as possible after presentation and recorded risk
factors for stroke, current treatment, and electrocardiogram
findings; measured impairment using the NIHSS [8]; and
collected variables for a previously validated ‘‘six simple variables’’
prognostic model (age, prior dependence, able to lift both arms
from the bed, able to walk without assistance, living alone at the
time of the event, and orientation in time and person) [4]. We
defined hypertension as a history of treated hypertension; ischemic
heart disease as a history of myocardial infarction, angina,
coronary artery bypass grafting, or percutaneous coronary
intervention; peripheral artery disease as a history of claudication,
peripheral artery intervention, or definite signs of vascular disease
of the legs (e.g., absent pedal pulses); cardiac failure as definite
signs of heart failure, or taking at least two medications for its
treatment; and independence prior to stroke as not requiring
assistance for washing, dressing, feeding, or toileting.
Measurement of Blood Markers
Clinicians drew blood on the same day as clinical assessment or,
for patients admitted to the hospital, as soon after assessment as
possible. A clinical laboratory measured total white cell count
(Beckman Coulter LH750 analyser) and blood glucose (Vitros
Chemistry analyser). Blood samples for IL-6, CRP, and fibrinogen
were transported to the laboratory on water ice, centrifuged to
obtain serum and EDTA-anticoagulated plasma, and stored at
280uC until analysed. We measured CRP and fibrinogen in
plasma by immunonephelometry (Prospec, Dade Behring Milton
Keynes, UK) using the manufacturer’s reagents and standards. We
assayed IL-6 by ELISA (R & D Systems, Oxford, UK). Intra- and
inter-assay coefficients of variation were 4.7% and 8.3%, 2.6%
and 5.3%, and 7.5% and 8.9%, respectively. We performed all
assays blind to stroke outcome.
Assessment of Outcome
We sent each patient a validated postal questionnaire at 6 mo
from his/her stroke onset date. The questionnaire measured
disability with the modified Rankin Scale (mRS), a standard tool
for examining outcome after stroke. We sent nonresponders a
repeat questionnaire. Each patient was ‘‘flagged’’ at the General
Register Office for Scotland, which provided information on the
date and place of death. We confirmed cause of death by
inspection of the relevant medical records. In primary analyses, we
dichotomised a patient’s outcome into ‘‘poor’’ if he/she was
dependent on others for activities of daily living (mRS scores 3, 4,
and 5) or dead, and ‘‘good’’ if he/she was independent in activities
of daily living (mRS 0,1, and 2) 6 mo after stroke onset. In
subsidiary analyses, we dichotomised patient outcome at 6 mo into
alive or dead.
Statistical Analysis
Association between marker levels and baseline
features. In a series of bivariate analyses, we compared
normally distributed baseline characteristic with Student’s t-tests,
proportions with x2 tests, and positively skewed data with
Wilcoxon rank sum tests. For the calculation of Pearson
correlation coefficients, we logarithmically transformed positively
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skewed blood marker data to obtain a normal distribution. We
examined the relationship between biomarker level and delay to
blood taking using multivariable regression analysis.
Association between marker levels and outcome. We
investigated the unadjusted associations between inflammatory
marker level and outcome with x2 for trend tests. We built a
logistic regression model for the association of each inflammatory
biomarker with poor or good outcome, with the terms from the
previously validated six simple variable model added sequentially.
We also examined logistic regression models for the association
between individual biomarkers and outcome, adjusting stepwise
for NIHSS, age, vascular risk factors, sex, and prior independence
and living alone (domains not part of the NIHSS). For these
analyses, we compared the upper and lower thirds of inflammatory
marker levels for the entire sample and modelled the marker levels
as linear variables. We stratified the analyses by NIHSS, OCSP,
delay to blood taking, and pathological stroke type to look for
evidence of effect modification.
Assessing the contribution of biomarkers to clinical
prognostic models. We assessed the additional contribution
of those inflammatory markers that were significantly associated
with poor outcome after adjustment to the previously validated six
simple variable model [4].
First, we assessed whether blood markers improved the
goodness of fit of existing models using the likelihood ratio
statistic. Second, to compare the ability of models to discriminate
between good and poor outcome, we calculated areas under
receiver operator curves (AUC). An AUC of 1 indicates perfect
discrimination and 0.5 no discrimination. Third, we assessed
calibration (whether the average predicted risk of poor outcome in
subgroups matches that observed in the cohort) with the Hosmer
Lemeshow x2 statistic. Fourth, we assessed the ability of the best
performing model including biomarkers to one without by
examining risk stratification tables [9]. We used the methods of
Pencina et al. [10] to calculate net reclassification improvement
(NRI). NRI is a measure that takes into account the correct
movement of individuals between categories of predicted risk (i.e.,
numbers moving correctly or incorrectly up or down) to estimate
overall improvement. We prespecified thresholds of,10%
and.90% for predicted probability of poor outcome as we
believe that one would need to be very certain of a good or poor
outcome before avoiding treatments such as thrombolysis or
selecting patients for palliative care only.
All p values reported are two-sided and we considered p,0.05
statistically significant. We performed statistical analyses with Stata
(Version 10.1, College Station, TX, USA).
Systematic Review
We searched Medline and EMBASE from 1966 to December
2008 for studies in patients with acute stroke that measured IL-6
and assessed clinical outcome. The search strategy included 13
terms for ischemic stroke and two for IL-6. Prognostic studies were
identified using high-sensitivity search terms [11], together with
common outcome measurements from stroke research (Rankin,
NIHSS, Glasgow outcome scale) (see MOOSE checklist, Text S1).
We included studies if they (a) reported results for patients with
acute stroke (not transient ischemic attack); (b) assayed a venous
IL-6 in stroke patients; (c) measured outcome using death,
disability, or handicap scales; and (d) reported results in a manner
that allowed calculation of OR for poor outcome or death per unit
increase in marker to allow comparison of measures of association
between studies. The result of the literature search is available on
request from the authors. We extracted data from logistic
regression models reporting the association between IL-6 and
poor outcome or death after stroke, and the degree of adjustment
for age, stroke severity, and other potential confounders. We
performed fixed effects meta-analysis with Stats Direct Version
2.7.2.
We prepared this paper with reference to the STROBE [12]
guidelines for reports of observational epidemiological studies, the
REMARK [13] guidelines for reports of prognostic variables, and
the MOOSE [14] guidelines for the meta-analysis of observational
studies.
Results
Baseline Characteristics
We assessed 1,408 patients, of whom 844 (60%) had blood
drawn for markers of inflammation. Of these, 785 (93%) had a
definite ischemic stroke, 16 (2%) a probable ischemic stroke, and
43 (5%) a hemorrhagic stroke. Those included were similar to
those who were not, in age, sex, and the proportions with
hypertension, peripheral, or cardiac vascular disease; diabetes; or
atrial fibrillation. On average, compared to those without
biomarker data, patients with biomarker data had milder strokes
(median NIHSS 1 versus 2, p,0.001; proportion total anterior
circulation stroke syndrome 7.7% versus 14.7%, p=0.001,
respectively), as patients admitted to the hospital and those with
more severe symptoms were less likely to be recruited because of
practical barriers to obtaining and processing research blood
samples and obtaining informed consent or assent [6]. Included
patients were also less likely to have a diagnosis of cardiac failure
(4.3% versus 8.3%, p=0.002). The median delay from stroke to
blood taking was 13 d (IQR 6 to 22 d). Of those patients who had
blood drawn for blood markers, 6-mo mRS data were available in
750/844 (89%) and vital status at 6 mo was available in all
patients. At 6 mo, of the 844 patients, 59 were dead and 238 were
dead or disabled. Data completeness is summarised in Figure 1.
Deaths were due to the initial or recurrent stroke (35/59, 59%);
vascular disease of the heart, legs, or bowel (9/59, 15%); cardiac
failure (5/59, 9%); cancer (5/59, 9%); and bowel perforation,
chronic obstructive pulmonary disease, or pneumonia (5/59, 8%).
For all markers there was a weak though statistically significant
(p,0.001) negative relationship between the natural logarithm of
marker and time. The Pearson correlation coefficients for the
relationship between time in days and the natural logarithm of
each marker were: glucose, r=20.07; white cell count, r=20.12;
fibrinogen, r=20.12; CRP, r=20.14; and IL-6, r=20.19. In
multivariate regression models with time as the independent
variable, after adjustment for age and stroke severity measured by
NIHSS, these relationships were even weaker and not statistically
significant.
Table 1 summarises the baseline data for all those patients from
whom blood was drawn for markers and for those with good and
poor outcome at 6 mo. Patients who died or had poor outcome
were older; had more severe strokes; and had more ischemic heart
disease, previous strokes or transient ischemic attacks, diabetes,
congestive cardiac failure, and atrial fibrillation. They were more
likely at the time of stroke to live alone, be dependent on others for
activities of daily living, be disorientated, have arm weakness, and
be unable to walk. They had higher levels of IL-6, CRP,
fibrinogen, white cell count, and glucose.
Relation of Markers to Outcome with and without
Adjustment for Other Factors
There were strong positive associations between marker levels
and the odds of poor outcome (Figure 2). The risk of poor outcome
rose by each third of IL-6 (x2 trend p,0.001), CRP (x2 trend
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p,0.001), fibrinogen (x2 trend p,0.001), white cell count (x2 trend
p=0.002), and glucose (x2 trend p=0.001). The risk of death also
rose by each third of marker (x2 trend p,0.001 for each marker)
(unpublished data), though in general the association between
marker thirds and death was stronger than for poor outcome.
After adjustment for age, and at the onset of stroke, whether the
patient lived alone, was independent of activities of daily living,
was orientated, was able to lift his/her arms or walk, the odds
ratios were attenuated for the association with poor outcome (top
versus bottom third: IL-6, OR: 3.1, 95% CI: 1.9–5.0; CRP, OR:
1.9, 95% CI: 1.2–3.1; fibrinogen, OR: 1.5, 95% CI: 1.0–2.4; white
cell count, OR: 2.1, 95% CI: 1.3–3.4; and glucose OR: 1.3, 95%,
CI: 0.8–2.1) and death (unpublished data). Adjustment for the
association between marker levels and poor outcome for NIHSS,
age, vascular risk factors, sex, and prior independence and living
alone led to only minor changes in the magnitude of these odds
ratios for the association with poor outcome. After additional
adjustment for other markers, only the association between IL-6
and poor outcome remained independently significant (OR: 2.4,
95% CI: 1.3–4.5). Further adjustment of the associations with
death was not performed because of the relatively small number of
events. There was no material difference in the magnitude,
direction, or significance of the association between IL-6, CRP,
and white cell count (data shown for IL-6) and outcome after
stratifying the analysis by stroke subtype, stroke severity, clinical
stroke syndrome, or delay to blood taking after stroke (Figure 3).
The crude increase in the odds of death or disability per unit
increase in marker level was lowest for CRP and highest for
fibrinogen, though the range of the fibrinogen (1.2–9.6 g/l) was
smaller than CRP (0.159–263 mg/l). After adjustment for the six
simple variables, the associations between IL-6, CRP, and white
cell count remained statistically significant (Table 2).
Does the Addition of Marker Data Improve the Utility of
Clinical Predictive Models?
We added data for markers with independent associations with
poor outcome (IL-6, CRP, and white cell count) as continuous
variables to the previously validated six simple variable model
(Table 3) [4]. Model fit was improved significantly after the
addition of IL-6 or white cell count, though not CRP. Model
calibration was adequate after the addition of IL-6, white cell
count, and CRP. However, AUC was improved significantly only
after the addition of IL-6 to the six simple variable model, though
not after the addition of white cell count or CRP alone. A model
with the six simple variables and all of the inflammatory markers
was well calibrated but had a similar AUC to a model with the six
simple variables and IL-6 alone (p=0.8). As the NIHSS and age
model was poorly calibrated in this cohort (Hosmer-Lemeshow x2
p=0.01), it was not examined further.
We compared the proportions of patients with predicted high
(.90%) and low (,10%) risks of poor outcome by the six simple
variable model with and without the addition of IL-6 (Table 4).
Figure 1. Flowchart of data available in the study. aResults are incomplete for glucose and white cell count, as for outpatients these results
were sometimes reported to the general practice rather than the central results database.
doi:10.1371/journal.pmed.1000145.g001
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The addition of IL-6 to the six simple variable model increased the
proportion of patients in the lowest risk category from 2.5% to
4.4% and the proportion in the highest risk category from 2.2% to
3.0%; that is, an extra 2.6% (95% CI: 1.7–4.1) were moved from
indeterminate (10%–90%) to determinate categories (.90%
or,10%). The models correctly classified those in the highest risk
category as having a poor outcome, in 91% (95% CI: 73–98) of
patients for the model including IL-6, and 94% (95% CI: 73–99)
for the model without. The models incorrectly classified patients in
the lowest risk category in 12% (95% CI: 5%–27%) for the model
including IL-6 and 16% (95% CI: 6%–38%) for the model with
the six simple variables alone. The NRI after the addition of
IL-6 to the six simple variable model (5%, p=0.014) was
small.
Table 1. Baseline characteristics of biomarker cohort and their association with death and poor outcome.
Characteristic
Total Cohort
(n=844)
Good Outcome at 6 mo
(mRS=0,1,2) (n=512)
Poor outcome at 6 mo
(mRS=3,4,5 or dead) (n=238) p-Value
Age, mean (SD) 72 (11) 70 (11) 75 (11) ,0.001a
Male sex, number (%) 445 (53) 275 (54) 115 (48) 0.169b
NIHSSd, median (IQR)e 1 (4) 1 (2) 4 (7) ,0.001c
Laboratory measurements, median (IQR)
Interleukin-6 (pg/ml) 4.0 (4.8) 3.3 (3.2) 6.1 (7.5) ,0.0001c
C-reactive protein (mg/l) 3.4 (8.1) 2.6 (5.7) 7.1 (18.8) ,0.0001c
Fibrinogen (g/l) 4.5 (1.6) 4.3 (1.4) 5.0 (1.9) ,0.0001c
White cell count (6109/l)f 8.0 (3.1) 7.7 (2.9) 8.5 (3.1) ,0.0001c
Glucose(mmol/l)g 5.6 (1.9) 5.5 (1.7) 6.0 (2.1) 0.0002c
Cholesterol (mmol/l), mean (SD) 5.2 (1.3) 5.2 (1.2) 5.1 (1.3) 0.189a
Pathological stroke type, number (%)
Definite ischemic stroke 785 (93) 484 (95) 215 (90) 0.006b
Definite hemorrhagic stroke 43 (5) 18 (4) 21 (9)
Probable ischemic stroke 16 (2) 10 (2) 2 (1)
OCSP ischemic stroke syndrome number (%)
Total anterior circulation infarction 53 (7) 10 (2) 32 (15) ,0.001b
Partial anterior circulation infarction 352 (44) 225 (46) 96 (44)
Lacunar infarction 221 (28) 143 (29) 53 (24)
Posterior circulation infarction 124 (16) 80 (16) 28 (13)
Unclassified 51 (6) 36 (7) 8 (4)
Six simple variable modelh number (%)
Living alone 324 (38) 327 (36) 105/237 (44) 0.033b
Independent pre-stroke 799 (95) 502 (98) 209 (88) ,0.001b
Normal verbal Glasgow coma scale 754 (90) 492/509 (97) 185/237 (78) ,0.001b
Able to lift both arms 749 (89) 494/511 (97) 180 (76) ,0.001b
Able to walk 640 (76) 464/511 (91) 117 (49) ,0.001b
Stroke risk factors number (%)
History of hypertension 453 (54) 244 (52) 143 (60) 0.047 b
Prior ischemic heart disease 234 (28) 125 (24) 86 (36) 0.001b
History of diabetes 103 (12) 52 (10) 41 (17) 0.006b
History of peripheral vascular disease 36 (8) 40 (8) 18/235 (8) 0.941b
History of cardiac failure 40 (5) 11/511 (2) 25/237 (11) ,0.001b
Atrial fibrillation (previous or current) 162 (19) 73 (14) 69 (29) ,0.001b
Prior stroke or transient ischemic attack 262 (31) 144 (28) 86 (36) 0.027b
Smoker (current or within 1 y) 275/829 (31) 163/508 (32) 73/232 (31) 0.886b
at-test.
bx2 test.
cNational Institute of Health Stroke Scale.
d482 good outcome and 224 poor outcome strokes.
eWilcoxon rank sum test.
f496 good outcome and 233 poor outcome strokes.
g471 good outcome and 218 poor outcome strokes.
hThe sixth variable in this model is age.
doi:10.1371/journal.pmed.1000145.t001
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Systematic Review and Meta-Analysis
The literature search identified 146 studies. We excluded studies
for the following reasons: they were non-systematic reviews (20),
they were unobtainable (3), participants did not have stroke at
baseline (75), they did not measure blood IL-6 levels (12), death or
disability was not reported (20), they reported odds ratios for the
association of IL-6 above and below a threshold (2) [15,16], they
reported correlation coefficients only (4) [17–20], they reported
mean levels in patients with good and bad outcomes only (5) [21–
25], or they did not report numerical results (1) [26]. We identified
four relevant studies(Table 5) [27–30] that yielded, for the
association between IL-6 and poor outcome, 1,037 patients, and
IL-6 and death 1,122 patients. The summary odds ratios were
comparable to the results of the current study (Figure 4).
Discussion
Statement of Main Findings
In this large cohort of stroke patients, we found that higher
levels of IL-6, CRP, and white cell count were independently and
significantly associated with poor outcome and death at 6 mo after
stroke. The association was independent of stroke severity, age,
and risk factors for recurrent stroke, though only IL-6 was
independent of other markers. The addition of IL-6 to a validated
prognostic model increased the proportion of patients with
predicted probabilities of a poor outcome of.90% or,10% by
only 2.8%, and the net classification index by 5%. These findings
lend support to the hypothesis that the inflammatory response is
associated with poor outcome after stroke. However, although the
measurement of the inflammatory response assessed with IL-6
improves prediction of poor outcome, in this cohort the degree
was so small that the use of these markers in routine practice is
unlikely to be helpful to clinicians aiming to predict the outcome of
their stroke patients, for example by selecting individuals for
aggressive treatment or palliative care.
Study Limitations and Potential Biases
We did not exclude patients with infection from the study, a
potential confounder as infection after stroke is associated both
with higher levels of inflammatory markers and with poor
outcome after stroke independently of other factors, as we sought
external validity to determine the role of markers in a clinical
setting. However, the delay between blood taking and stroke did
leave time for the development of complications in some of the
more severely affected stroke patients, so a rise in inflammatory
markers due to infection rather than brain damage due to stroke
may have been responsible for at least part of the observed
association. The cohort, consisting of a mixture of outpatients
Figure 2. Association between levels of inflammatory marker versus poor outcome (mRS.2 or death). Expressed as ratio of odds in
middle and top thirds of marker distribution, versus the referent lower third. Dotted line indicates OR= 1 (i.e., same odds as lower third). ORs are
reported unadjusted and adjusted for six simple variables (age, living alone, independent of activities of daily living prior to stroke, normal verbal
Glasgow coma scale, able to lift arms from bed, able to walk). Tertiles of IL-6: 2.8 and 5.5 pg/l; CRP: 1.9 and 7.1 mg/l; fibrinogen: 4.1 and 5.1 g/l; white
cell count: 7.0 and 9.16109 cells/l; and glucose: 5.2 and 6.3 mmol/l.
doi:10.1371/journal.pmed.1000145.g002
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and hospital inpatients, contained relatively mild stroke patients,
so models generated from the whole cohort may not be
applicable to cohorts containing only patients with severe strokes,
as our models may have a ceiling effect at higher stroke severities.
We were limited in our ability to recruit more patients with very
severe strokes chiefly because of practical barriers to blood taking
and informed consent. We dichotomised the Oxford Handicap
Scale, measured by postal questionnaire, into ‘‘independent’’ and
‘‘dependent.’’ Although crude, this measure has both internal and
external validity [31].
We assessed inflammatory marker levels only at the time of
assessment. While serial measurement might have provided more
information, a single measurement was strongly associated with
outcome but still did not much add to existing prognostic models.
It seems unlikely that the additional trouble of obtaining serial
samples will be outweighed by additional predictive power.
The use of AUC to choose between predictive models is a
subject of some controversy. The AUC analysis is based on rank
comparison, which may be problematic for populations in whom
the risk of an event is very low (e.g., incident stroke in
asymptomatic cohorts) [32]. However, as the risk of poor outcome
after stroke is high in this cohort (32%), the use of the AUC seems
reasonable. While in this study IL-6 has an association with poor
outcome, an extremely strong and independent association needs
Figure 3. Association between upper third and lower third of IL-6 by subgroups. Each OR is adjusted for the six simple variables (age, living
alone, independent of activities of daily living prior to stroke, normal verbal GCS, able to lift arms from bed, able to walk), and the estimate for the
whole cohort is given by the vertical dashed line. OR of.1 indicates that increased levels of marker are associated with poorer outcome in that
category of patient. The p values are derived from tests for heterogeneity. LACS, lacunar stroke syndrome; PACS, partial anterior stroke syndrome;
POCS, posterior circulation stroke syndrome; TACS, total anterior stroke syndrome.
doi:10.1371/journal.pmed.1000145.g003
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to be demonstrated before a marker meaningfully improves
classification accuracy [33]. We assessed the additional predictive
utility of IL-6 with risk stratification tables applying cut points for
predicted outcome that are relevant for stroke practice for the
treatments that are currently available. Less stringent thresholds of
risk could be examined, though it is hard to see how they would be
useful in making decisions about individual patients. We have not
demonstrated that IL-6 improves prediction in our cohort using
our chosen thresholds. Our conclusions would be strengthened by
replication of our findings in a validation dataset.
The systematic review is limited in scope, as several other
studies relevant to the association between IL-6 and death or poor
outcome reported their results either as a comparison of odds of
poor outcome above and below optimised cut points or as
correlation coefficients; hence, extraction of data per unit increase
in marker level was not possible.
Interpretation
We have demonstrated that blood markers of the acute inflamma-
tory response, in particular IL-6, are associated with death and poor
outcome after stroke. The results from this study are broadly
comparable to other studies of IL-6 and poor outcome or death after
stroke (Figure 4), which supports the generalisability of the findings.
The strengths of the current study in comparison to other
studies merit consideration. It is much larger than previous reports
and has used a measure of handicap (the mRS) as well as death to
define poor outcome. It has used a validated prognostic model to
adjust for confounding by stroke severity, age, and prior
dependence and has carefully explored the role of these markers
in clinical decision making, which, though often proposed, has not
been examined before.
IL-6 is induced by tumour necrosis factor a and IL-1b, and then
leads to the releases of CRP, fibrinogen, and cell adhesion
molecules, though the cellular origin of IL-6 after stroke is not
clear. Whether the higher levels of IL-6 are a bystander to, or a
cause of, poor outcome is uncertain. Mice deficient in IL-6 showed
similar stroke volume and disability at 24 h as mice with normal IL-
6 expression [34], suggesting that it may simply be part of the
inflammatory response to stroke and not directly pathogenic. The
association of IL-6 with poor outcome has been demonstrated in
many conditions such as HIV [35], many cancers [36], and
occurrence of vascular disease including stroke [37], making it more
plausible that IL-6 is a general marker of disease severity rather than
part of numerous disease-specific pathways to poor outcome.
Conclusions
In this large cohort of stroke patients, blood markers of the acute
inflammatory response were associated with poor outcome after
stroke, though only IL-6 showed independent association after
adjustment for confounding factors, including levels of other
markers. In this cohort, the addition of IL-6 to a previously
validated prognostic model added to the prediction of outcome,
Table 2. The association between marker levels and poor outcome after stroke.
Markers Odds Ratio Per Unit Increase in Marker Level (95% CI)
Unadjusted Estimate Adjusted for Six Simple Variable
Adjusted for NIHSS, Age, Risk Factors for Recurrent
Strokea, Living Alone, and Prior Independence
IL-6 (pg/ml) 1.14 (1.10–1.17) 1.07 (1.03–1.11) 1.05 (1.01–1.09)
CRP (mg/l) 1.02 (1.01–1.03) 1.01 (1.00–1.01) 1.01 (1.00–1.01)
Fibrinogen (g/l) 1.35 (1.21–1.51) 1.12 (0.98–1.28) 1.05 (0.90–1.21)
White cell count (6109/l) 1.14 (1.08–1.21) 1.08 (1.01–1.16) 1.06 (0.99–1.14)
Glucose (mmol/l) 1.06 (1.00–1.12) 1.04 (0.97–1.12) 0.96 (0.87–1.05)
aPrevious diabetes, history of cardiovascular disease, history of peripheral vascular disease, history of cardiac failure, history of hypertension, current or history of atrial
fibrillation.
doi:10.1371/journal.pmed.1000145.t002
Table 3. Performance of models to predict poor outcome after stroke.
Model
Likelihood
Ratio Statistic p-Valuea
Hosmer-Lemeshow x2
(Estimate of Model Calibration) p-Valueb AUC (95% CI) pc
1. Six simple variables Reference Reference 6.2 0.63 0.78 (0.74–0.83) Reference
2. Six simple variables+IL-6 10.9 ,0.01 8.0 0.43 0.80 (0.76–0.84) ,0.01
3. Six simple variables+CRP 3.4 0.06 6.7 0.57 0.78 (0.75–0.82) 0.09
4. Six simple variables+white cell count 5.62 0.02 3.3 0.91 0.78 (0.74–0.82) 0.53
5. Six simple variables+white cell count+CRP+IL-6 13.39 ,0.01 12.0 0.15 0.80 (0.76–0.83) 0.01
Performance of six simple variables model (age, living alone, independent of activities of daily living prior to stroke, normal verbal GCS, able to lift arms from bed, able
to walk) and addition of IL-6, CRP, and white cell count as continuous variables.
aThe likelihood ratio test compares a goodness of fit between models with and without biomarker data. p,0.05 indicates that the model with biomarkers gives a
significantly better fit of the data.
bThe Hosmer Lemeshow test compares the observed number of people with events to that predicted by the model. p.0.05 indicates that the model is well calibrated.
cAUC=1 indicates perfect discrimination of a model between patients with good and bad outcomes. p,0.05 indicates that the model containing biomarkers has a
significantly higher AUC than one without.
doi:10.1371/journal.pmed.1000145.t003
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but by an amount that is unlikely to be useful in clinical practice.
Whether or not inflammatory markers are useful in prediction of
recurrent stroke [38,39] or other vascular events is a separate
question, which requires further study.
Supporting Information
Text S1 MOOSE checklist.
Found at: doi:10.1371/journal.pmed.1000145.s001 (0.06 MB
DOC)
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Variable Model Alone
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Variable Model with IL- 6
Total %
Reclassified
,10%
10%–
50%
50%–
90% .90%
,10%
Patients (n) 14 5 — — —
% reclassified — 26 — — 26
Observed % poor outcome 14 20 — — —
10%–50%
Patients (n) 19 534 4 — —
% reclassified 3 — 7 — 4
Observed % poor outcome 11 20 75 — —
50%–90%
Patients (n) — 4 137 10 -
% reclassified — 3 — 7 9
Observed % poor outcome — 50 69 90 -
.90%
Patients (n) — — 4 13 —
% reclassified — — 23 — 23
Observed % poor outcome — — 100 92 —
Total
Patients (n) 33 543 145 23 —
Observed % poor outcome 12 20 70 91 —
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Editors’ Summary
Background. Every year, 15 million people have a stroke. In
the US alone, someone has a stroke every 40 seconds and
someone dies from a stroke every 3–4 minutes. Stroke occurs
when the blood supply to the brain is suddenly interrupted
by a blood clot blocking a blood vessel in the brain (ischemic
stroke, the commonest type of stroke) or by a blood vessel in
the brain bursting (hemorrhagic stroke). Deprived of the
oxygen normally carried to them by the blood, the brain cells
near the blockage die. The symptoms of stroke depend on
which part of the brain is damaged but include sudden
weakness or paralysis along one side of the body, vision loss
in one or both eyes, and confusion or trouble speaking or
understanding speech. Anyone experiencing these
symptoms should seek medical assistance immediately
because prompt treatment can limit the damage to the
brain. Risk factors for stroke include age (three-quarters of
strokes occur in people over 65 years old), high blood
pressure, and heart disease.
Why Was This Study Done? Many people are left with
permanent disabilities after a stroke. An accurate way to
predict the likely long-term outcome (prognosis) for
individual patients would help clinicians manage their
patients and help relatives and patients come to terms
with their changed circumstances. Clinicians can get some
idea of their patients’ likely outcomes by assessing six simple
clinical variables. These include the ability to lift both arms
and awareness of the present situation. But could the
inclusion of additional variables improve the predictive
power of this simple prognostic model? There is some
evidence that high levels in the blood of inflammatory
markers (for example, interleukin-6 and C-reactive protein)
are associated with poor outcomes after stroke—
inflammation is the body’s response to infection and to
damage. In this prospective cohort study, the researchers
investigate whether inflammatory markers are associated
with poor outcome after stroke and whether the addition of
these markers to the six-variable prognostic model improves
its predictive power. Prospective cohort studies enroll a
group of participants and follow their subsequent progress.
What Did the Researchers Do and Find? The researchers
recruited 844 patients who had had a stroke (mainly mild
ischemic strokes) in Edinburgh. Each patient was assessed
soon after the stroke by a clinician and blood was taken for
the measurement of inflammatory markers. Six months after
the stroke, the patient or their relatives completed a postal
questionnaire that assessed their progress. Information
about patient deaths was obtained from the General
Register Office for Scotland. Dependency on others for the
activities of daily life or dying was recorded as a poor
outcome. In their statistical analysis of these data, the
researchers found that raised levels of several inflammatory
markers increased the likelihood of a poor outcome. For
example, after allowing for age and other factors, individuals
with interleukin-6 levels in the upper third of the measured
range were three times as likely to have a poor outcome as
patients with interleukin-6 levels in the bottom third of the
range. A systematic search of the literature revealed that
previous studies that had looked at the potential association
between interleukin-6 levels and outcome after stroke had
found similar results. Finally, the researchers found that the
addition of inflammatory marker levels to the six-variable
prognostic model did not substantially improve its ability to
predict outcome after stroke for this cohort of patients.
What Do These Findings Mean? These findings provide
additional support for the idea that increased levels of
inflammatory markers are associated with a poor outcome
after stroke. However, because patients with infections were
not excluded from the study, infection may be responsible
for part of the observed association. Importantly, these
findings also show that although the inclusion of
inflammatory markers in the six variable prognostic model
slightly improves its ability to predict outcome, the
magnitude of this improvement is too small to warrant the
use of these markers in routine practice. Whether the
measurement of inflammatory markers might be useful in
the prediction of recurrent stroke—at least a quarter of
people who survive a stroke will have another one within 5
years—requires further study.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000145.
N This study is further discussed in a PLoS Medicine
Perspective by Len Kritharides
N The US National Institute of Neurological Disorders and
Stroke provides information about all aspects of stroke (in
English and Spanish); the Know Stroke site provides
educational materials about stroke prevention, treatment,
and rehabilitation (in English and Spanish)
N The Internet Stroke Center provides detailed information
about stroke for patients, families and health professionals
(in English and Spanish)
N The UK National Health Service also provides information
for patients and their families about stroke (in several
languages)
N MedlinePlus provides links to further resources and advice
about stroke (in English and Spanish)
N The six simple variable model for prediction of death or
disability after stroke is available here: http://dcnapp1.dcn.
ed.ac.uk/scope/
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